Summary of study ST000248

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000200. The data can be accessed directly via it's Project DOI: 10.21228/M8JC79 This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  |  Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data (Contains raw data)
Study IDST000248
Study TitleMetabolic heterogeneity in Glioblastoma
Study TypeMultiple patient-derived cell lines screening
Study Summary2 cell populations [slow and fast-cycling cells] were isolated from 3 different patient-derived glioblastoma stem cell lines [L0, L1, L2].
University of Florida
LaboratoryGarrett Lab
Last NameDeleyrolle
First NameLoic
AddressR3-226 Academic Research Building, Department of Biochemistry and Molecular Biology, PO Box 100245, Gainesville, FL 32610-0245
Submit Date2015-03-24
Num Groups2
Total Subjects6
Study CommentsLine names: L0, L1 & L2. Subpopulation names: slow-cycling cells [S], fast-cycling cell [F]. Sample list: L0-S, L0-F, L1-S, L1-F, L2-S, L2-F
Raw Data AvailableYes
Raw Data File Type(s).mzXML
Uploaded File Size1 GB
Analysis Type DetailLC-MS
Release Date2016-09-23
Release Version1
Loic Deleyrolle Loic Deleyrolle application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000200
Project DOI:doi: 10.21228/M8JC79
Project Title:Metabolic heterogeneity in Glioblastoma
Project Summary:Glioblastoma (GB) is the most common and complex primary brain tumor in adults and has a dismal prognosis, which is attributed largely to the extreme heterogeneity in the cells that make up the cancer and the continual molecular, genetic and metabolic adaptations driving tumor initiation, propagation and resistance to conventional treatments. The most important clinical target to prevent these mechanisms of initiation, propagation and disease recurrence may be a subset of tumor cells, cancer stem cells. Hence, identifying targetable key features of this population is of great interest for the elaboration of strategies to prevent disease initiation and propagation as well as recurrence post treatments. In response to i) the limited success to treat GB that remains universally fatal, ii) the evidences pointing to tumor heterogeneity as the greatest obstacle to achieve therapeutic efficacy and iii) the increasing understanding and importance of bioenergetics in tumor biology and the critical need to integrate metabolism into treatment paradigms, we propose a new model residing in the unique and unprecedented hypothesis of an association between GB management, a distinct slow-cycling cancer stem cell subpopulation and metabolic targeting.
Institute:University of Florida
Department:McKnight Brain Institute, Neurosurgery
Last Name:Deleyrolle
First Name:Loic